Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 12/20 | 0.40 |
| ▸ | CCND1 | P24385 | 9/20 | 0.40 |
| ▸ | CCND2 | P30279 | 6/20 | 0.40 |
| ▸ | CCND3 | P30281 | 6/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.40 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957977 | 0.93 | TNK2 (0.46) | TNK2CDK4CCND1CCND2CCND3 | |
| SCHEMBL2953623 | 0.88 | TNK2 (0.57) | TNK2FGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2959696 | 0.87 | TNK2 (0.58) | TNK2FGFR1SRC | |
| SCHEMBL2952193 | 0.85 | TNK2 (0.64) | TNK2STK17ACDK4CCND1CCND2 | |
| SCHEMBL2952192 | 0.81 | TNK2 (0.47) | TNK2CDK4CCND1CCND3CCNA2 | |
| SCHEMBL30338613 | 0.77 | TNK2 (0.77) | TNK2 | |
| SCHEMBL2956900 | 0.76 | TNK2 (0.58) | TNK2SRC | |
| SCHEMBL2956876 | 0.73 | TNK2 (0.69) | TNK2SRC | |
| SCHEMBL2955951 | 0.73 | TNK2 (0.42) | TNK2SRC | |
| SCHEMBL2957964 | 0.73 | TNK2 (0.50) | TNK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | TNK2 113/4885STK17A 94/4885CDK4 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.